Tumour volume is an independent predictor of prostate‐specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer
Bradford A. Nelson(Vanderbilt University Medical Center), Michael S. Cookson(University of Oklahoma Health Sciences Center), Joseph A. Smith(King's College London), Sam S. Chang(Vanderbilt University), Nancy Wells(Vanderbilt University Medical Center), Scott B. Shappell(Vanderbilt University), Scott B. Farnham(Vanderbilt University)
Cited by 113
Related Papers
The Long-Term Effect of Doxazosin, Finasteride, and Combination Therapy on the Clinical Progression of Benign Prostatic Hyperplasia
|New England Journal of Medicine|2003|2k
Guideline for the Management of Clinically Localized Prostate Cancer: 2007 Update
|The Journal of Urology|2007|1.1k
Variation in the Definition of Biochemical Recurrence in Patients Treated for Localized Prostate Cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer Update Panel Report and Recommendations for a Standard in the Reporting of Surgical Outcomes
|The Journal of Urology|2007|845
Robot-assisted radical cystectomy versus open radical cystectomy in patients with bladder cancer (RAZOR): an open-label, randomised, phase 3, non-inferiority trial
|The Lancet|2018|779
The Treated Natural History of High Risk Superficial Bladder Cancer: 15-year Outcome
|The Journal of Urology|1997|555